sars-cov-2 infection; sars-cov-2 infection; this is a spontaneous report received from a contactable reporter(s) (consumer or other non hcp) from the ra. a female patient received bnt162b2 (comirnaty), administration date nov2021 (batch/lot number: unknown) as dose 3 (booster), single, administration date apr2021 (batch/lot number: unknown) as dose 2, single and administration date jan2021 (batch/lot number: unknown) as dose 1, single for covid-19 immunisation. the patient's relevant medical history and concomitant medications were not reported. it was reported that patient has not had symptoms associated with covid-19. the following information was reported: drug ineffective (medically significant) with onset 03jan2022, outcome "unknown", suspected covid-19 (medically significant) with onset 03jan2022, outcome "recovered" (05jan2022) and all described as "sars-cov-2 infection". the patient underwent the following laboratory tests and procedures: sars-cov-2 test: negative, notes: no - negative covid-19 test. patient was not enrolled in clinical trial. the report does not relate to possible inflammation of the heart (myocarditis or pericarditis). no follow-up attempts are possible; information about lot/batch number cannot be obtained. no further information is expected.; sender's comments: linked report(s) : gb-pfizer inc-202200298677 same patient/product/ reporter, different dose number/ event

test name: covid-19 virus test; test result: negative ; comments: no - negative covid-19 test

na

na